Literature DB >> 17243135

Intra-individual variation in blood flow velocities in cerebral arteries of children with sickle cell disease.

Donald J Brambilla1, Scott T Miller, Robert J Adams.   

Abstract

BACKGROUND: Children with sickle cell disease (SCD) are at elevated risk of stroke. Risk increases with blood flow velocity in selected cerebral arteries, as measured by transcranial Doppler (TCD) ultrasound, and use of TCD to screen these patients is widely recommended. Interpretation of TCD results should be based on knowledge of intra-individual variation in blood flow velocity, information not currently available for sickle cell patients. PROCEDURES: Between 1995 and 2002, 4,141 subjects, 2-16 years old, with homozygous SCD or Sbeta0-thalasemmia and no history of stroke were screened with TCD, including 2,018 subjects screened in one clinical trial (STOP), 1,816 screened in another (STOP 2), and 307 screened in an interim ancillary prospective study. The 812 subjects with >or=2 examinations<6 months apart were selected for analysis, including 242 (29.8%) subjects with normal average velocities (i.e., <170 cm/sec), 350 (43.1%) subjects with conditional velocities (i.e., 170-199 cm/sec), and 220 (27.1%) subjects with abnormal velocities (i.e., >or=200 cm/sec). The intra-subject standard deviation of TCD velocity was estimated from the difference between velocities at the first two interpretable examinations on each subject.
RESULTS: An intra-subject standard deviation of 14.9 cm/sec was obtained. Seven (0.9%) subjects had unusually large and unexplained differences between velocities at the two examinations (range of absolute differences: 69-112 cm/sec).
CONCLUSIONS: While stroke risk is well demonstrated to increase with increasingly abnormal TCD velocity, given the relatively large intra-subject variability, one TCD examination is generally not sufficient to characterize stroke risk in this patient population. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17243135      PMCID: PMC2867598          DOI: 10.1002/pbc.21142

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  12 in total

1.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.

Authors:  L B Goldstein; R Adams; K Becker; C D Furberg; P B Gorelick; G Hademenos; M Hill; G Howard; V J Howard; B Jacobs; S R Levine; L Mosca; R L Sacco; D G Sherman; P A Wolf; G J del Zoppo
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

2.  Sickle cell disease and stroke: primary prevention and transcranial Doppler.

Authors:  Robert J Adams; Steve Pavlakis; E Steve Roach
Journal:  Ann Neurol       Date:  2003-11       Impact factor: 10.422

3.  Comparison of transcranial color Doppler imaging (TCDI) and transcranial Doppler (TCD) in children with sickle-cell anemia.

Authors:  A M Jones; J J Seibert; F T Nichols; D L Kinder; K Cox; J Luden; E M Carl; D Brambilla; S Saccente; R J Adams
Journal:  Pediatr Radiol       Date:  2001-07

4.  Cerebrovascular accidents in sickle cell disease: rates and risk factors.

Authors:  K Ohene-Frempong; S J Weiner; L A Sleeper; S T Miller; S Embury; J W Moohr; D L Wethers; C H Pegelow; F M Gill
Journal:  Blood       Date:  1998-01-01       Impact factor: 22.113

5.  Stroke prevention trial in sickle cell anemia.

Authors:  R J Adams; V C McKie; D Brambilla; E Carl; D Gallagher; F T Nichols; S Roach; M Abboud; B Berman; C Driscoll; B Files; L Hsu; A Hurlet; S Miller; N Olivieri; C Pegelow; C Scher; E Vichinsky; W Wang; G Woods; A Kutlar; E Wright; S Hagner; F Tighe; M A Waclawiw
Journal:  Control Clin Trials       Date:  1998-02

6.  Stroke prevention in sickle cell disease (STOP) study guidelines for transcranial Doppler testing.

Authors:  F T Nichols; A M Jones; R J Adams
Journal:  J Neuroimaging       Date:  2001-10       Impact factor: 2.486

7.  Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease.

Authors:  Robert J Adams; Donald Brambilla
Journal:  N Engl J Med       Date:  2005-12-29       Impact factor: 91.245

8.  Long-term stroke risk in children with sickle cell disease screened with transcranial Doppler.

Authors:  R J Adams; V C McKie; E M Carl; F T Nichols; R Perry; K Brock; K McKie; R Figueroa; M Litaker; S Weiner; D Brambilla
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

9.  Stroke and conversion to high risk in children screened with transcranial Doppler ultrasound during the STOP study.

Authors:  Robert J Adams; Donald J Brambilla; Suzanne Granger; Dianne Gallagher; Elliott Vichinsky; Miguel R Abboud; Charles H Pegelow; Gerald Woods; Elizabeth M Rohde; Fenwick T Nichols; Anne Jones; Judith P Luden; Latonya Bowman; Susan Hagner; Knashawn H Morales; E Steve Roach
Journal:  Blood       Date:  2004-01-29       Impact factor: 22.113

10.  The use of transcranial ultrasonography to predict stroke in sickle cell disease.

Authors:  R Adams; V McKie; F Nichols; E Carl; D L Zhang; K McKie; R Figueroa; M Litaker; W Thompson; D Hess
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

View more
  7 in total

1.  Transcranial Doppler in the evaluation of infants treated with retrograde ventriculosinus shunt.

Authors:  Matheus Fernandes de Oliveira; Manoel Jacobsen Teixeira; Marcelo de Lima Oliveira; Edson Bor Seng-Shu; Karen Andrade Norremose; Fernando Campos Gomes Pinto
Journal:  Childs Nerv Syst       Date:  2016-09-14       Impact factor: 1.475

2.  Effect of transfusion therapy on transcranial Doppler ultrasonography velocities in children with sickle cell disease.

Authors:  Janet L Kwiatkowski; Eunsil Yim; Scott Miller; Robert J Adams
Journal:  Pediatr Blood Cancer       Date:  2010-12-23       Impact factor: 3.167

3.  End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain.

Authors:  Ann T Farrell; Julie Panepinto; C Patrick Carroll; Deepika S Darbari; Ankit A Desai; Allison A King; Robert J Adams; Tabitha D Barber; Amanda M Brandow; Michael R DeBaun; Manus J Donahue; Kalpna Gupta; Jane S Hankins; Michelle Kameka; Fenella J Kirkham; Harvey Luksenburg; Shirley Miller; Patricia Ann Oneal; David C Rees; Rosanna Setse; Vivien A Sheehan; John Strouse; Cheryl L Stucky; Ellen M Werner; John C Wood; William T Zempsky
Journal:  Blood Adv       Date:  2019-12-10

4.  Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial).

Authors:  Najibah A Galadanci; Shehu Umar Abdullahi; Leah D Vance; Abdulkadir Musa Tabari; Shehi Ali; Raymond Belonwu; Auwal Salihu; Aisha Amal Galadanci; Binta Wudil Jibir; Halima Bello-Manga; Kathleen Neville; Fenella J Kirkham; Yu Shyr; Sharon Phillips; Brittany V Covert; Adetola A Kassim; Lori C Jordan; Muktar H Aliyu; Michael R DeBaun
Journal:  Am J Hematol       Date:  2017-06-15       Impact factor: 10.047

Review 5.  Genetic, laboratory and clinical risk factors in the development of overt ischemic stroke in children with sickle cell disease.

Authors:  André Rolim Belisário; Célia Maria Silva; Cibele Velloso-Rodrigues; Marcos Borato Viana
Journal:  Hematol Transfus Cell Ther       Date:  2017-11-26

6.  American Society of Hematology 2020 guidelines for sickle cell disease: prevention, diagnosis, and treatment of cerebrovascular disease in children and adults.

Authors:  M R DeBaun; L C Jordan; A A King; J Schatz; E Vichinsky; C K Fox; R C McKinstry; P Telfer; M A Kraut; L Daraz; F J Kirkham; M H Murad
Journal:  Blood Adv       Date:  2020-04-28

7.  Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.

Authors:  Russell E Ware; Barry R Davis; William H Schultz; R Clark Brown; Banu Aygun; Sharada Sarnaik; Isaac Odame; Beng Fuh; Alex George; William Owen; Lori Luchtman-Jones; Zora R Rogers; Lee Hilliard; Cynthia Gauger; Connie Piccone; Margaret T Lee; Janet L Kwiatkowski; Sherron Jackson; Scott T Miller; Carla Roberts; Matthew M Heeney; Theodosia A Kalfa; Stephen Nelson; Hamayun Imran; Kerri Nottage; Ofelia Alvarez; Melissa Rhodes; Alexis A Thompson; Jennifer A Rothman; Kathleen J Helton; Donna Roberts; Jamie Coleman; Melanie J Bonner; Abdullah Kutlar; Niren Patel; John Wood; Linda Piller; Peng Wei; Judy Luden; Nicole A Mortier; Susan E Stuber; Naomi L C Luban; Alan R Cohen; Sara Pressel; Robert J Adams
Journal:  Lancet       Date:  2015-12-06       Impact factor: 79.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.